ImmunityBio Inc. Common Stock vs State Street Corporation Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10.69 (market cap $10.51B), while State Street Corporation Common Stock trades at $174.48 (market cap $48.10B). The key difference: State Street Corporation Common Stock is far larger — about 4.6× ImmunityBio Inc. Common Stock's market cap, and State Street Corporation Common Stock pays a 2.1% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and State Street Corporation Common Stock for 0 Days on average.
| IBRX | STT | |
|---|---|---|
Market Cap | $10.51B | $48.10B |
Volume | 10,445,785 | 2,033,865 |
Sector | Health | Financials |
52-Week High | $11.55 | $194.26 |
52-Week Low | $1.98 | $111.00 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.97B | $74.64B |
Dividend Yield | — | 2.1% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →